Emergent Medical Partners, LLP β Full Portfolio
36 tracked investments Β· listed companies and verified rows first
EBR Systems develops the WiSE cardiac pacing system, a leadless and physiologic medical device for treating heart failure patients.
HealthtechMedical DevicesSilicon Valley, AU
Parker Willis(Executive Officer)inAllan Will(Executive Chair)inJohn McCutcheon(President, Chief Executive Officer)inMark Cowan(Executive Officer)inStephen O'Conner(Executive Officer)Richard Riley(Executive Officer)
Co-investorsAscension VenturesRunway Growth CapitalSplit Rock Partners
Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.
BiotechHealthtechMedical DevicesLexington, US
HARITH RAJAGOPALAN(Executive Officer, Director)inJAY CAPLAN(Executive Officer, Director)inJay Caplan(Executive Officer, Director)inHarith Rajagopalan(Executive Officer, Director)inLISA DAVIDSON(Executive Officer)inDiane Marcou(Executive Officer)in
Co-investorsBessemer Venture PartnersCatalio Capital Management, LPMithril Capital ManagementPolaris PartnersVeltro Argento
Heartflow provides an AI-based analysis that converts a coronary CTA scan into a personalized 3D model of the heart, assessing anatomy and physiology to help diagnose and manage coronary artery disease (CAD).
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesRedwood City, US
Christopher K. Zarins(Executive Officer, Director)inCharles A. Taylor(Executive Officer, Director)inNicky Espinosa Hayes(Executive Officer)John Stevens(Executive Officer, Director)inH. Baird Radford, III(Executive Officer)John Farquharin
Co-investorsBain Capital Life SciencesBlue Venture FundsKhosla VenturesLifeforce CapitalLotus CapitalSilver Lake Partners+1 more
InterVene, Inc. is a medical device company that has developed a fully integrated mechanical thrombectomy system to treat venous in-stent restenosis and residual thrombotic venous obstructions and occlusions.
BiotechHealthtechMedical DevicesMountain View, US
Fletcher Wilson(Executive Officer, Director)in
BoardThomas Fogarty(Director)Mel Schatz(Director)
Board seatThomas J. FogartyΒ· per SEC Form D Β· $3M raise Β· filed Jun 2017
Co-investorsLaunchCapitalRiverVest Venture PartnersTreo Ventures, Llc
Arterys provides AI clinical applications for medical imaging that integrate directly into existing PACS and EHR systems to assist physicians with diagnosis and treatment decisions.
AI & Machine LearningHealthtechMedical DevicesSan Francisco, US
Fabien Beckers(Executive Officer, Director)John Axerio-Cilies(Executive Officer, Director)
BoardRobert Brownell(Director)Steve Dow(Director)
Co-investorsAsset Management CompanyKhosla VenturesTemasek
HealthtechRedwood City, US
John B. Simpson(Executive Officer, Director)Himanshu N. Patel(Executive Officer)Mark Weinswig(Executive Officer)Jeffrey M. Soinski(Executive Officer, Director)Matthew Ferguson(Executive Officer)
BoardJames B. McElwee(Director)
Co-investorsLucas Venture Group
HardwareHealthtechMedical DevicesMenlo Park, US
Laura N. Dietch(Executive Officer, Director)Kurt Sparks(Executive Officer)
BoardSharon Stevenson, DVM, PhD(Director)inDrew Hoffmann(Director)Robert Brownell(Director)Thomas Fogarty, MD(Director)
Co-investorsOkapi Venture Capital
HealthtechHayward, US
GUY DIPIERRO(Director)ALAN LEVY, PH.D.(Executive Officer, Director)ANTHONY RIMAC(Executive Officer)ALAN LEVY(Executive Officer, Director)
BoardELIZABETH ROCKETT(Director)WENDE HUTTON(Director)in
Co-investorsFountain Healthcare PartnersKaiser Permanente VenturesMission Bay CapitalCanaan Partners
Cianna Medical develops oncology products for breast cancer care, including targeted APBI (accelerated partial breast irradiation) therapy and wire-free tumor localization tools for lesions from breast to soft tissue.
BiotechHealthtechMedical DevicesAliso Viejo, US
Gordon H. Busenbark(Executive Officer)Charles Bracken(Executive Officer)Jill Anderson(Executive Officer, Director)in
BoardTom Umbel(Director)Nancy Olson(Director)Tiba Aynechi, Ph.D.(Director)
Non-invasive robotic ablation treatment for cardiac arrhythmias; acquired by Varian in April 2019.
Devices for percutaneous repair of cardiac valves; acquired by Abbott Vascular in October 2009.
Co-investorsNew Enterprise Associates (NEA)
BiotechPalo Alto, US
William Thomas McClellan(Executive Officer, Director, Promoter)
BoardDonald Ross(Director)Robert Brownell(Director)Cortland Bohacek(Director)
Focal Rx develops bioabsorbable medical devices, specifically the BioZorb 3D Bioabsorbable Marker, for clinical and surgical applications.
Medical Devices
HeRO Graft is a fully subcutaneous arteriovenous access device for hemodialysis patients with central venous stenosis, designed to reduce infection rates and improve long-term vascular access reliability.
Medical Devices
Co-investorsMutual Capital Partners
Drug-device combination product for post-operative pain; acquired by The Medicines Company in January 2013.
IT Asset Management Group provides IT asset disposition (ITAD), secure data destruction, and electronics recycling services for retired IT equipment.
Circular EconomyEnterprise Software
Co-investorsTreo Ventures, Llc
Miniaturized cardiac rhythm devices; acquired by St.
Devices for minimally invasive laparoscopic surgery; ENCLOSE II device acquired by Vitalitec; acquired by Intuitive Surgical.
HealthtechGlen Burnie, US
Mark Janofsky(Executive Officer)Greg Stokes(Executive Officer)John Spitznagel(Executive Officer, Director)Michael Coppola(Executive Officer)
BoardEran Nadav(Director)Steve Grenfell(Director)
Co-investors1315 Capital
Early-stage company developing a diagnostic for melanoma.
The page describes a custom guitar building business that has suspended custom build orders after purchasing a shop called Guitars Plus, and now sells one-of-a-kind guitars from a location in downtown Victoria.
ConsumerVictoria, CA
Relievant offers the Intracept Procedure, a minimally invasive, FDA-cleared medical intervention designed to relieve chronic low back pain caused by vertebrogenic pain.
Medical DevicesRedwood City, US
Alex DiNello(Executive Officer, Director)
BoardRichard Mott(Director)Justin Klein(Director)inBrent Ahrens(Director)inJason Lettman(Director)John Ryan(Director)
Co-investorsCanaan PartnersLightstone VenturesNew Enterprise Associates (NEA)Vensana Capital
HealthtechSan Francisco, US
Reza Naima(Executive Officer, Director)
Co-investorsLaunchCapitalEmergent Medical PartnersLaunch CapitalNorwich Ventures
HealthtechSan Jose, US
Duncan Maitland(Director)inMichael Henson(Executive Officer, Director)Edward F. Ruppel, Jr(Executive Officer, Director)Carolyn M. Bruguera(Executive Officer)James Y Lancaster(Executive Officer, Director)in
BoardThom Rasche(Director)
Co-investorsEarlybird Venture CapitalTaiwania Capital
Continuous suture passing device for minimally invasive orthopedic shoulder surgery.
Standard Bariatrics develops the Titan SGSβ’ Stapler, a specialized surgical device designed for sleeve gastrectomy procedures that creates consistent and symmetrical gastric pouches using an anatomy-based approach.
Medical Devices
Co-investorsCincyTechHatteras Venture PartnersJobsOhio VenturesRC CapitalRiverVest Venture PartnersUS Venture Partners
BiotechHealthtechPompano Beach, US
Laura Tyler Perryman(Director)Regina Groves(Executive Officer, Director)Virginia Sullivan(Executive Officer)Marc Loev(Director)Richard Chen Mao(Director)Gary Perryman(Director)
Co-investorsSV Health Investors
Suture Ease develops and commercializes proprietary devices for laparoscopic surgery, with a flagship CrossBow Fascial Closure System that uses a "snare guide" technology and suture passer for trocar site closure.
Medical DevicesSan Jose, US
Scott Heneveld(Founder & COO)Kirt Kirtland(CEO)in
Accessory devices for trans-catheter aortic valve replacement procedures.
Transcatheter mitral valve replacement device; acquired by Medtronic in August 2015.
Devices for delivery of brachytherapy in gynecological cancer patients; acquired by Varian Medical Systems in March 2011.
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.




